Health Economics›Breast cancer›Advanced or metastatic disease first-line

Advanced or metastatic disease first-line

Breast cancer · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Fulvestrant, Inavolisib, Palbociclib Variant #01 Partial	PIK3CA	R 26 181	28d	16.1 mo	34.0 mo	18	R 471 253 PFS proxy	3
Fulvestrant and Palbociclib Variant #01	PIK3CA	R 26 181	28d	7.3 mo	27.0 mo	8	R 209 446 PFS proxy	3

2 of 2 regimens shown